Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ABT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Multiple daily injections of insulin | Type 1 Diabetes | N/A · NCT07423637 | Recruiting |
| Inotropic Support | Cardiogenic Shock | N/A · NCT04682483 | Recruiting |
| Vasopressor | Cardiogenic Shock | N/A · NCT04682483 | Recruiting |
Also used in these trials (approved or third-party drugs, not ABT's own candidates): Sotagliflozin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ABT holds $4.3B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vanguard Capital Management | Institution (13G, 5%+) | 130,676,776 | 7.55% | 2026-03-31 |
| Daniel J Starks Director · +7,105 options |
Insider | 6,751,361 | 0.39% | 2026-04-24 |
| Robert B Ford CHAIRMAN AND CEO, Director |
Insider | 522,664 | 0.03% | 2026-08-25 |
| Daniel Gesua Sive Salvadori EVP AND GROUP PRESIDENT |
Insider | 146,377 | 0.01% | 2026-02-27 |
| Mary K Moreland EXECUTIVE VICE PRESIDENT |
Insider | 118,136 | 0.01% | 2026-11-05 |
| Philip P Boudreau EVP AND CFO |
Insider | 82,316 | 0.00% | 2026-09-01 |
| Kevin T Conroy Director · +551 options |
Insider | 81,230 | 0.00% | 2026-09-23 |
| Christopher J Scoggins EXECUTIVE VICE PRESIDENT |
Insider | 77,126 | 0.00% | 2026-02-27 |
| Louis H. Morrone EXECUTIVE VICE PRESIDENT |
Insider | 70,724 | 0.00% | 2026-08-11 |
| Nancy McKinstry Director · +2,305 options |
Insider | 41,010 | 0.00% | 2026-04-24 |
| Eric Shroff Senior Vice President |
Insider | 39,164 | 0.00% | 2026-02-27 |
| Elizabeth C. Cushman EVP, GC AND SECRETARY |
Insider | 38,013 | 0.00% | 2026-06-27 |
Share count 1,731,941,601 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →